compounded semaglutide news Compound versions of GLP-1 drugs for weight loss halted by FDA States cracking down on compounding

Cardiovascular Effects Dose-dependent increases in heart rate were observed with retatrutide: Heart rate increases peaked at approximately 24 weeks Gradually declined thereafter while remaining elevated above baseline This pattern is similar to that observed with other GLP-1 receptor agonists[4] The clinical significance of these heart rate changes requires further evaluation in larger and longer-term studies

Bioluminux Clinical Research is an emerging Integrated Research Organization (IRO) with investigator sites making medical innovation possible by engaging in rigorous clinical investigation studies in the UK and the U.S.

Tuesday, May 5th 7:30 PM EST | 4:30 PM PST Cant attend live

Andrew Blauvelt, MD, shared his insights on the use of GLP-1s for treating patients with psoriasis.

We hope that this article has provided you with helpful information about semaglutide for weight loss

To reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight